Osteoporosis

1. High-Yield Summary

• Definition & Diagnostic Core: Osteoporosis is a progressive systemic skeletal disorder characterized by low bone mineral density (BMD) and microarchitectural deterioration of bone tissue, predisposing individuals to heightened bone fragility and susceptibility to low-energy fragility fractures.
• Diagnostic Benchmarks: Dual-energy X-ray absorptiometry (DXA) establishes the operational diagnosis with a T-score ≤ -2.5 standard deviations at the lumbar spine (L1-L4), femoral neck, or total hip, or by the clinical occurrence of a low-trauma fragility fracture at the spine, hip, wrist, or humerus regardless of BMD.
• Primary Fracture Sites: Vertebral compression fractures (most common overall), hip/proximal femur fractures (highest morbidity and 20–30% 1-year mortality), distal radius fractures (Colles’ fracture, often the earliest sentinel fragility event), and proximal humerus fractures.
• Pharmacologic Sequencing: For very high fracture risk (e.g., T-score ≤ -3.0, prior vertebral fracture within 12 months, multiple fragility fractures), anabolic therapy (teriparatide, abaloparatide, or romosozumab) is recommended first, followed by antiresorptive consolidation (bisphosphonates or denosumab) to maintain newly formed mineralized bone.
• Surgical Principles: Fixation in osteoporotic bone requires load-sharing constructs, fixed-angle locked plating, bicortical purchase, cement augmentation/fenestrated screws, or long cephalomedullary nails for peritrochanteric hip fractures; cemented femoral stems are strongly favored in hip hemiarthroplasty or total hip arthroplasty to minimize catastrophic periprosthetic fracture risk.

2. Anatomy

Understanding the microstructural, macrostructural, and cellular anatomy of bone is vital for interpreting bone density loss, fracture mechanics, and implant anchorage failure in osteoporotic patients.

• Cortical vs. Trabecular Bone Architecture:
  • Cortical (Compact) Bone: Constitutes approximately 80% of skeletal mass and surrounds the diaphyseal shafts and outer shell of all bones. It is arranged into Haversian systems (osteons) with concentric lamellae surrounding a central neurovascular canal. In osteoporosis, intracortical Haversian remodeling accelerates, leading to cortical thinning, endosteal resorption, and cortical porosity (tunneling).
  • Trabecular (Cancellous) Bone: Constitutes 20% of skeletal mass but accounts for up to 80% of total surface area and metabolic turnover. Located predominantly in vertebral bodies, the femoral neck and intertrochanteric region, the distal radius metaphysis, and proximal humerus. It consists of a 3-dimensional lattice of plates and rods (struts). Osteoporosis causes preferential loss of horizontal stabilizing cross-struts, leading to microarchitectural disconnection, buckling of unsupported vertical trabeculae, and catastrophic loss of compressive load capacity.
• Cellular Machinery of Bone Remodeling:
  • Osteocytes: Terminally differentiated osteoblasts embedded within lacunar spaces connected by canalicular networks. Osteocytes act as the primary mechanosensory cells of bone, detecting microcracks and fluid shear stress. In response to unloading or microdamage, osteocytes secrete sclerostin (SOST gene product) and Dkk-1, which bind LRP5/6 receptors to inhibit the anabolic Wnt/beta-catenin signaling cascade.
  • Osteoclasts: Multinucleated giant cells derived from hematopoietic monocyte/macrophage precursors. Activated by macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kappa B ligand (RANKL). They attach to the mineralized matrix via alpha-v-beta-3 integrins (sealing zone), creating Howship’s lacunae, and secrete hydrochloric acid (dissolves inorganic hydroxyapatite) and cathepsin K (cleaves organic type I collagen matrix).
  • Osteoblasts: Mononuclear cells derived from multipotent mesenchymal stem cells under the direction of master transcription factors Runx2 and Osterix. Synthesize osteoid (predominantly type I collagen, osteocalcin, and alkaline phosphatase) and regulate mineral precipitation. Osteoblasts also secrete osteoprotegerin (OPG), a soluble decoy receptor that binds RANKL, neutralizing osteoclastogenesis.
• Vascular and Neural Innervation: Cortical bone perfusion is maintained via endosteal nutrient arteries running centrifugally toward periosteal plexuses under normal physiologic conditions. In osteoporotic and fragile elderly bone, reduced endosteal capillary density impairs secondary fracture healing and soft tissue revascularization. The richly innervated periosteum carries sensory nociceptors and sympathetic nerve fibers (responsible for the acute somatic pain of macro- and micro-trabecular fractures).

3. Pathogenesis

Bone remodeling operates through a tightly coupled balance within Basic Multicellular Units (BMUs), where osteoclastic resorption typically equals osteoblastic bone deposition over a complete remodeling cycle of 120–200 days. Osteoporosis develops when bone resorption chronically outpaces bone formation, leading to a net negative skeletal balance.

• Postmenopausal Estrogen Deficiency (Type I Osteoporosis):
  • Estrogen suppresses pro-inflammatory cytokine expression (interleukin-1, interleukin-6, TNF-alpha) by osteoblasts, marrow stromal cells, and T-lymphocytes.
  • Abrupt estrogen decline at menopause lifts this inhibition, triggering massive upregulation of stromal RANKL expression while decreasing osteoprotegerin (OPG) synthesis.
  • The elevated RANKL/OPG ratio stimulates excessive osteoclast proliferation, prolonged osteoclast survival, and heightened resorption depth within trabecular plates. Deep resorption pits cause complete perforation of horizontal trabeculae rather than simple thinning, permanently erasing the architectural template required for osteoblastic repair.
  • Accelerated phase: Bone mineral loss can reach 2–5% per year during the first 5–8 years post-menopause, predominantly impacting trabecular-rich skeletal sites (lumbar spine, distal radius).
• Age-Related / Senile Osteoporosis (Type II Osteoporosis):
  • Affects both men and women older than 70 years, characterized by gradual, steady bone loss (approximately 0.5–1% per year).
  • Pathophysiology involves intrinsic stem cell senescence with reduced osteoblast lifespan and impaired recruitment, diminished synthesis of local growth factors (IGF-1, TGF-beta), and impaired renal 1-alpha-hydroxylase activity leading to decreased 1,25-dihydroxyvitamin D synthesis.
  • Secondary hyperparathyroidism develops as a homeostatic response to impaired intestinal calcium absorption, driving continuous slow intracortical remodeling, increased cortical porosity, and thinning of both cortical and trabecular compartments (predisposing to hip fractures).
• Secondary Causes of Accelerated Bone Loss:
  • Glucocorticoid-Induced Osteoporosis (GIOP): The most common secondary cause. Glucocorticoids directly induce osteoblast and osteocyte apoptosis, inhibit Runx2 transcription, stimulate RANKL expression, decrease intestinal calcium absorption, and promote renal hypercalciuria. Bone loss occurs rapidly within 3–6 months of initiating systemic corticosteroids (≥ 5 mg prednisone daily equivalent).
  • Endocrine Disorders: Primary hyperparathyroidism (cortical bone resorption, classically at the 33% radius), hyperthyroidism, hypogonadism (including androgen deprivation therapy in prostate cancer), Cushing syndrome, and type 1 diabetes mellitus.
  • Gastrointestinal & Malabsorptive: Celiac disease, Crohn’s disease, post-bariatric Roux-en-Y gastric bypass, chronic liver disease, leading to calcium and fat-soluble vitamin D malabsorption.
  • Hematologic & Rheumatologic: Multiple myeloma (excess local osteoclast-activating factors, e.g., MIP-1alpha, Dkk-1), systemic mastocytosis, rheumatoid arthritis (systemic inflammation and localized periarticular osteopenia).

4. Natural History

Osteoporosis is historically described as the “silent thief” because progressive bone loss occurs insidiously without pain or physical symptoms until the index fragility fracture occurs.

• Epidemiology: Affects over 200 million individuals globally. In North America and Europe, approximately 1 in 3 women and 1 in 5 men older than 50 years will sustain an osteoporotic fragility fracture during their remaining lifetime. Peak incidence of distal radius fractures occurs in the 50s and 60s, vertebral compression fractures in the 60s and 70s, and hip fractures predominantly beyond age 75.
• The Imminent Fracture Cascade: The occurrence of a single fragility fracture exponentially escalates the risk of subsequent fractures. Following an initial vertebral compression fracture, the risk of sustaining a second vertebral fracture within the subsequent 12 months is elevated 5-fold (the “imminent fracture window”). Similarly, a distal radius fracture carries a 2- to 4-fold elevated risk of a future hip fracture.
• Morbidity and Mortality:
  • Hip Fractures: Carry a catastrophic 1-year all-cause mortality rate of 20–30%. Less than 50% of surviving patients regain their pre-fracture level of functional mobility and independence; 25% require permanent nursing home admission.
  • Vertebral Compression Fractures: While approximately two-thirds of vertebral fractures are asymptomatic or clinically silent at onset, progressive multiple collapse causes thoracic hyperkyphosis, restrictive pulmonary lung disease, early satiety and weight loss due to abdominal compression, chronic intractable sagittal back pain, and elevated mortality.

5. Clinical Presentation

History

A comprehensive history in patients presenting for bone health evaluation or after low-energy trauma must focus on:

• Mechanism of Injury: Establish whether the index injury occurred from low-energy mechanisms (e.g., fall from standing height or lower, lifting a grandchild, stepping off a curb, or spontaneous onset during bed repositioning).
• Height Loss & Postural Changes: Prospective loss of > 2 cm (0.8 inches) or historical lifetime loss of > 4 cm (1.5 inches) from maximal young-adult height is a sensitive indicator of occult vertebral compression fractures.
• Prior Fracture History: Any prior fracture sustained after age 40, including non-displaced wrist fractures or historical ribs cracked after coughing.
• Secondary Risk Factor Inventory: Family history of parental hip fracture (vital FRAX input), current cigarette smoking, excessive alcohol intake (≥ 3 units/day), early menopause (< 45 years), prolonged amenorrhea, history of eating disorders, and chronic systemic illnesses (rheumatoid arthritis, IBD, CKD).
• Medication Review: Cumulative systemic glucocorticoid exposure (> 3 months at ≥ 5 mg prednisone), aromatase inhibitors (anastrozole, letrozole), androgen deprivation therapy (leuprolide), proton pump inhibitors (PPIs), antiepileptics (phenytoin, carbamazepine), and selective serotonin reuptake inhibitors (SSRIs).

Physical Exam

Physical examination must evaluate spinal posture, localized bony tenderness, thoracic biomechanics, and neuromuscular fall risk factors:

• Wall-Occiput Distance (WOD): Patient stands upright with heels and back flat against a vertical wall. Inability to touch the occiput to the wall while maintaining a horizontal Frankfort plane (WOD > 0 cm) indicates thoracic hyperkyphosis, with WOD > 2 cm carrying high specificity for occult thoracic vertebral compression fractures.
• Rib-Pelvis Distance: Measure the vertical fingerbreadths between the inferior costal margin (12th rib) and the superior anterior iliac crest in the mid-axillary line. A distance of ≤ 2 fingerbreadths suggests lumbar height collapse and severe spinal osteoporosis.
• Spine Percussion Tenderness: Direct focal percussion over spinous processes. Point tenderness over a specific thoracic or lumbar spinous process correlates strongly with an acute or subacute vertebral compression fracture.
• Neurologic Examination: Assessment of lower extremity motor groups, sensory dermatomes, deep tendon reflexes, and babinski/clonus to rule out spinal canal stenosis, retropulsed bone fragments, or conus/cauda equina compression.
• Functional Mobility & Fall Risk Assessment:
  • Timed Up and Go (TUG) Test: Rising from an armchair, walking 3 meters, turning, returning, and sitting. A time > 12–14 seconds indicates impaired balance, high fall risk, and need for physical therapy/gait aids.
  • Four-Stage Balance Test & 30-Second Chair Stand: Assesses core stability, lower extremity quadriceps power, and static balance.

6. Imaging and Diagnostic Studies

Diagnostic evaluation integrates quantitative densitometry, morphological radiography, advanced cross-sectional imaging for acute collapse, and focused laboratory screening to exclude secondary metabolic etiologies.

• Dual-Energy X-ray Absorptiometry (DXA / DEXA):
  • Gold Standard Method: Measures areal Bone Mineral Density (aBMD in g/cm²) by passing two low-dose X-ray beams of differing energy levels through tissue, subtracting soft tissue attenuation from bone attenuation.
  • T-score: The number of standard deviations the patient’s aBMD deviates from the mean peak bone mass of a healthy, young sex-matched reference population (age 20–29). Used for postmenopausal women and men aged ≥ 50 years.
  • Z-score: The number of standard deviations the patient’s aBMD deviates from an age-, sex-, and ethnicity-matched population. Used for premenopausal women, men < 50 years, and children. A Z-score ≤ -2.0 is defined as “below the expected range for age” and demands comprehensive secondary etiology workup.
  • Standard Scan Anatomical Sites: Lumbar spine (L1–L4 total; exclude individual vertebrae altered by severe degenerative osteophytosis, sclerosis, aortic calcification, or prior fracture), femoral neck, and total hip.
  • Forearm DXA (33% / One-Third Radius): Indicated when hip or lumbar spine scans are uninterpretable (e.g., bilateral total hip arthroplasties, extensive spine instrumentation), in patients with severe obesity exceeding DXA scanner table weight limits, and specifically in primary hyperparathyroidism (which preferentially attacks cortical bone).
• Fracture Risk Assessment Tool (FRAX®): A computer algorithm developed by the World Health Organization that integrates clinical risk factors (age, sex, BMI, previous fracture, parental hip fracture, smoking, glucocorticoids, rheumatoid arthritis, secondary causes, alcohol ≥ 3 units/day) with or without femoral neck BMD to calculate the 10-year probability of:
  • Major Osteoporotic Fracture (clinical spine, hip, forearm, or humerus). Intervention threshold typically ≥ 20%.
  • Hip Fracture. Intervention threshold typically ≥ 3%.
• Plain Radiographs:
  • Poor sensitivity for early diagnosis: requires 30–50% of bone mineral content to be lost before osteopenia is distinctly visible on standard radiographs.
  • Key radiographic signs: “Pencil-thin” cortices, loss of secondary horizontal trabeculae with relative accentuation of primary vertical load-bearing trabeculae, “ghost-like” vertebral bodies, and structural vertebral height loss (anterior wedge, biconcave/codfish vertebra, or complete crush collapse).
• Magnetic Resonance Imaging (MRI): Essential when evaluating acute vs. chronic vertebral compression fractures, assessing for posterior wall retropulsion into the spinal canal prior to cement augmentation, and differentiating benign osteoporotic fractures from pathologic fractures due to metastatic disease or multiple myeloma:
  • Acute Benign Fracture: Focal band-like hypointensity on T1-weighted images, hyperintensity on T2-STIR fat-suppressed sequences representing bone marrow edema, preserved normal marrow signal in the non-fractured portion of the vertebral body, and absence of soft tissue epidural/paravertebral mass.
  • Pathologic / Malignant Collapse: Diffuse complete replacement of vertebral body marrow on T1, extension of abnormal signal into the pedicles and posterior elements, convex posterior cortex bulging into the canal, and soft tissue epidural or paravertebral mass.
• Laboratory Screening Workup: Mandatory baseline laboratory testing to rule out treatable secondary causes prior to pharmacotherapy initiation:
  • Complete Blood Count (CBC) and Erythrocyte Sedimentation Rate (ESR) / C-Reactive Protein (CRP).
  • Serum Calcium (ionized or albumin-corrected), Phosphorus, Alkaline Phosphatase.
  • Serum Creatinine, Blood Urea Nitrogen, and estimated GFR (critical for guiding bisphosphonate eligibility).
  • Serum 25-hydroxyvitamin D [25(OH)D]: target level > 30 ng/mL (75 nmol/L).
  • Intact Parathyroid Hormone (PTH) and Thyroid-Stimulating Hormone (TSH).
  • Serum Protein Electrophoresis (SPEP) with immunofixation and serum free light chains (screen for multiple myeloma).
  • 24-hour urine collection for calcium, sodium, and creatinine (identifies hypercalciuria vs. malabsorptive hypocalciuria).
  • Tissue transglutaminase antibodies (tTG-IgA) for occult celiac disease in unexplained bone loss.

7. Classification

Standardized classifications establish operational diagnostic criteria, distinguish primary from secondary systemic forms, and quantify morphological severity of vertebral compression fractures.

Genant Semiquantitative Classification of Vertebral Fractures: Utilized in vertebral fracture assessment (VFA) and spinal radiographs to quantify height loss across anterior, middle, and posterior vertebral margins:

8. Treatment

Medical / Nonoperative

Medical management forms the bedrock of osteoporosis care and consists of baseline lifestyle optimization combined with risk-stratified pharmacotherapy:

• Nutritional & Lifestyle Foundation:
  • Elemental Calcium: 1000 mg/day for men aged 50–70; 1200 mg/day for women ≥ 51 and men ≥ 71. Dietary sources preferred. Calcium carbonate requires gastric acid (take with meals); calcium citrate is absorbed independently of gastric acid and preferred in elderly patients on PPI therapy or with achlorhydria.
  • Vitamin D3 (Cholecalciferol): 800–2000 IU/day to maintain 25(OH)D levels > 30 ng/mL. In severe deficiency (< 20 ng/mL), repletion with 50,000 IU ergocalciferol or cholecalciferol weekly for 8 weeks is standard before transitioning to maintenance dosing.
  • Mechanical Loading Exercise: Weight-bearing exercise (brisk walking, low-impact aerobics) stimulates osteocyte mechanotransduction; progressive resistance strength training improves dynamic muscular balance and lowers fall incidence.
• Antiresorptive Pharmacotherapies:
  • Oral Bisphosphonates: Alendronate (70 mg orally once weekly) or Risedronate (35 mg orally once weekly). Inhibit farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway, promoting osteoclast apoptosis. Administration instructions are strict: take first thing in the morning with a full glass of plain water, 30–60 minutes before any food/other medications, remaining upright for 30 minutes to prevent chemical esophagitis. Contraindicated in esophageal motility disorders and severe renal impairment (eGFR < 35 mL/min).
  • Intravenous Bisphosphonates: Zoledronic acid (5 mg IV annually infused over ≥ 15 minutes). Completely bypasses gastrointestinal intolerance. Contraindicated if creatinine clearance < 35 mL/min or in acute hypocalcemia. Pre-dose hydration and acetaminophen/ibuprofen prophylaxis reduce acute-phase post-infusion flu-like symptoms.
  • RANKL Inhibitor: Denosumab (60 mg subcutaneously every 6 months). Fully human monoclonal antibody that binds and neutralizes RANKL, preventing osteoclast maturation and activity. Not cleared by the kidneys; can be utilized in chronic kidney disease (stages 1–4), but carries heightened risk of severe hypocalcemia in CKD stage 5/dialysis. Critical Clinical Warning: Denosumab cannot be stopped abruptly. Its antiresorptive effect rapidly wanes within 6–9 months of a missed dose, triggering an osteoclast rebound phenomenon with massive bone turnover and multiple rebound vertebral compression fractures. Patients discontinuing denosumab must be transitioned to a potent bisphosphonate (e.g., zoledronic acid or oral alendronate) 6 months after the last injection.
  • Selective Estrogen Receptor Modulators (SERMs): Raloxifene (60 mg orally daily). Estrogen agonist on bone mineral matrix and lipid metabolism, antagonist in breast and uterine endometrium. Reduces vertebral fracture risk; neutral on non-vertebral and hip fracture risk. Increases risk of venous thromboembolism (VTE).
• Anabolic (Bone-Forming) Pharmacotherapies:
  • PTH / PTHrP Receptor Agonists: Teriparatide [rhPTH(1-34), 20 mcg SC daily] and Abaloparatide [synthetic PTHrP(1-34) analog, 80 mcg SC daily]. Intermittent daily exposure stimulates osteoblast differentiation and matrix deposition ahead of resorption, creating an “anabolic window.” Approved for up to 24 months of lifetime cumulative therapy. Black box warning for osteosarcoma removed based on long-term post-marketing surveillance data, but contraindicated in Paget’s disease, prior skeletal radiation therapy, unexplained elevated alkaline phosphatase, or preexisting hypercalcemia.
  • Sclerostin Monoclonal Antibody: Romosozumab (210 mg SC monthly for 12 doses). Binds sclerostin to relieve inhibition of the canonical Wnt/beta-catenin pathway, producing a potent dual effect: strongly stimulates bone formation while simultaneously suppressing bone resorption. Limited to a 12-month treatment course. Black Box Warning: Should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Must be followed immediately by an antiresorptive agent to maintain bone density gains.

Operative

Surgical intervention in osteoporotic bone focuses on stable fracture fixation, rapid patient mobilization to prevent recumbency-related complications, and pain relief through vertebral augmentation:

• Principles of Osteoporotic Fracture Fixation:
  • Fixed-Angle Locked Plating: Acts as an “internal-external fixator.” Stability relies on the screw-plate thread interface rather than friction between plate and poor-quality bone cortex, significantly reducing screw toggle and pullout.
  • Load-Sharing Intramedullary Nails: Superior to extramedullary side-plates in peritrochanteric hip fractures (unstable intertrochanteric and subtrochanteric patterns) due to reduced bending moment and load transmission along the mechanical axis of the femur.
  • Augmentation Techniques: Use of fenestrated screws injected with polymethylmethacrylate (PMMA) or calcium phosphate cements to augment screw purchase in severe osteoporotic cancellous bone (e.g., pedicle screws in spine deformity, cephalomedullary screws in geriatric hip fractures).
  • Arthroplasty vs. Fixation: In displaced femoral neck fractures (Garden III/IV) in elderly osteoporotic patients, primary arthroplasty (hemiarthroplasty or total hip arthroplasty) with cemented femoral stems is the gold standard, providing immediate full weight-bearing and eliminating the high rates of nonunion (20–30%) and avascular necrosis associated with internal fixation.
• Vertebral Augmentation (Kyphoplasty & Vertebroplasty):
  • Percutaneous Balloon Kyphoplasty (BKP): Transpedicular or extrapedicular cannulation of the collapsed vertebral body, inflation of an inflatable bone tamp to create a cavity and partially restore vertebral body height, followed by controlled low-pressure injection of viscous PMMA cement. Indicated for severe, incapacitating focal pain from acute/subacute (< 6–12 weeks) vertebral compression fractures with MRI-confirmed marrow edema failing conservative analgesia and bracing.
  • Percutaneous Vertebroplasty (PVP): Direct injection of high-viscosity PMMA into the trabecular space under fluoroscopic control without cavity creation.

Indications & Contraindications

Explicit clinical criteria determine the appropriateness of pharmacologic and surgical interventions:

• Indications for Pharmacotherapy (NOF / AACE Guidelines):
  • History of hip or vertebral fragility fracture (clinical or asymptomatic morphometric).
  • T-score ≤ -2.5 at the femoral neck, total hip, or lumbar spine.
  • T-score between -1.0 and -2.5 (osteopenia) AND a 10-year probability of hip fracture ≥ 3% or major osteoporotic fracture ≥ 20% on country-specific FRAX calculation.
• Indications for Upfront Anabolic Therapy (Very High Risk): T-score ≤ -3.0, multiple spine fractures, fracture while adherent to antiresorptive therapy, or very low BMD with prior fragility fracture within 12 months.
• Contraindications:
  • Bisphosphonates: eGFR < 35 mL/min, esophageal stricture/achalasia (oral), uncorrected hypocalcemia.
  • Denosumab: Uncorrected hypocalcemia (must repletion calcium/vitamin D prior to administration).
  • Teriparatide / Abaloparatide: Hypercalcemia, history of skeletal radiation therapy, bone metastases, Paget’s disease.
  • Romosozumab: Myocardial infarction or stroke within preceding 12 months; uncorrected hypocalcemia.
  • Vertebral Augmentation: Asymptomatic healed fracture without marrow edema, active local osteomyelitis/discitis or systemic sepsis, severe uncorrectable coagulopathy, posterior wall retropulsion with acute spinal cord or cauda equina compression.

9. Outcome

Modern multimodal osteoporotic care yields dramatic, reproducible reductions in fracture incidence, improves quality of life, and attenuates excess post-fracture mortality:

• Antiresorptive Efficacy:
  • Oral bisphosphonates (alendronate, risedronate) reduce vertebral fracture incidence by 40–50% and hip fracture incidence by 30–50% over 3 years in patients with preexisting osteoporosis or prior fractures.
  • Intravenous zoledronic acid provides a 70% relative risk reduction in vertebral fractures, a 41% reduction in hip fractures, and demonstrates a statistically significant 28% reduction in all-cause mortality when initiated post-hip fracture repair.
  • Denosumab reduces vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% over 36 months, with continuous progressive lumbar spine and hip BMD increases over 10 years of ongoing treatment.
• Anabolic Efficacy:
  • Teriparatide induces a 65% reduction in new vertebral fractures and a 53% reduction in non-vertebral fragility fractures over 18–24 months, with profound increases in trabecular connectivity and volumetric bone density.
  • Romosozumab achieves rapid, unprecedented bone mineral gains (12.7% lumbar spine BMD increase at 12 months) and a 73% relative risk reduction in new vertebral fractures compared to placebo, maintained when transitioned to denosumab or alendronate.
• Vertebral Augmentation Functional Outcomes: Percutaneous balloon kyphoplasty and vertebroplasty in carefully selected patients with acute painful compression fractures and MRI marrow edema achieve significant, rapid pain relief (visual analog scale reduction within 24–48 hours), reduced bed-rest immobility, improved pulmonary capacity, and decreased 1-year mortality compared to non-operative immobilization.

10. Complications

Complications encompass rare adverse consequences of long-term antiresorptive pharmacotherapy, procedural risks of bone cement augmentation, and surgical hardware failure in fragile host bone:

• Atypical Femur Fractures (AFFs):
  • Definition & Mechanism: Low-trauma stress fractures localized to the subtrochanteric region or femoral shaft, associated with prolonged antiresorptive suppression of bone turnover (> 5 years of bisphosphonates or denosumab) and microdamage accumulation.
  • Radiographic Features (ASBMR Criteria): Originates on the lateral femoral cortex, transverse or short oblique orientation, non-comminuted, presence of localized periosteal and endosteal “beaking” or flaring at the fracture site, with bilateral involvement in up to 30% of cases.
  • Management: Immediate cessation of antiresorptive therapy, full-length contralateral femur radiographs (to evaluate for impending bilateral fracture), avoidance of weight-bearing, prophylactic cephalomedullary nailing for incomplete fractures with pain or cortical lucency, and transition to anabolic therapy (teriparatide) to stimulate healing.
• Medication-Related Osteonecrosis of the Jaw (MRONJ):
  • Definition: Exposed non-vital bone in the maxillofacial region persisting for > 8 weeks in a patient with current or prior antiresorptive/antiangiogenic exposure and no history of craniofacial radiation therapy.
  • Incidence: Very rare in osteoporosis dosing regimens (estimated at 1 in 10,000 to 1 in 100,000 patient-years), compared to significantly higher rates in oncologic high-dose monthly regimens.
  • Prevention: Comprehensive dental examination and completion of invasive dentoalveolar surgical procedures prior to initiating potent antiresorptives; meticulous oral hygiene maintenance.
• Denosumab Rebound Vertebral Fractures: Sudden cessation or delayed administration of denosumab triggers an overshoot of osteoclast activity and rapid bone loss, culminating in multiple cascade vertebral compression fractures within 6–18 months. Never discontinue denosumab without bridging antiresorptive therapy.
• Surgical & Biomechanical Complications:
  • Implant Cutout & Fixation Failure: Cephalomedullary lag screw or helical blade cutout through the osteoporotic superior femoral head; failure to place the implant in the inferior/central quadrant with a tip-apex distance (TAD) < 25 mm drastically increases failure rates.
  • Periprosthetic Fractures: Insertion of uncemented, press-fit femoral stems into thin, brittle osteoporotic cortices (Dorr Type C “stovepipe” femur) carries high intraoperative fracture risk; cemented fixation is mandatory.
  • Vertebral Augmentation Cement Leakage: PMMA extravasation into perivertebral venous plexuses leading to pulmonary cement embolism, or into the spinal canal/neuroforamina causing acute radiculopathy or spinal cord compression.

11. Pearls and Pitfalls

• Pearl – The “Imminent Fracture Window”: Treat any acute fragility fracture as an orthopaedic emergency of bone health. Initiating bone-protective medical evaluation during the index hospital stay or acute fracture clinic visit captures patients during the highest-risk 12-month window for recurrent fracture.
• Pearl – Cemented Stems in Geriatric Arthroplasty: Always cement the femoral component in geriatric hip fractures or hip osteoarthritis in patients with poor bone quality. Registry data universally confirms that cemented stems have significantly lower 90-day periprosthetic fracture rates and reoperation rates compared to uncemented hydroxyapatite-coated stems in osteoporotic bone.
• Pearl – Thigh Pain on Bisphosphonates: Any patient on long-term bisphosphonate or denosumab therapy reporting new-onset dull groin or mid-thigh aching must receive bilateral full-length femur radiographs immediately to rule out early stress reaction/beaking of an atypical femur fracture before catastrophic displacement occurs.
• Pitfall – Abrupt Denosumab Cessation: Never allow a patient to stop denosumab without transitioning to a bisphosphonate. The surge in bone resorption can cause catastrophic loss of all gained BMD within 12 months and cause cascading multiple vertebral fractures.
• Pitfall – Starting Potent Antiresorptives in Severe Hypocalcemia: Always check serum calcium and 25-hydroxyvitamin D before administering IV zoledronic acid or subcutaneous denosumab. Suppressing bone resorption in a patient with profound secondary hyperparathyroidism or vitamin D deficiency triggers refractory symptomatic tetany and severe hypocalcemia.
• Pitfall – Dismissing DXA Sclerosis Artifacts: Degenerative disc disease, facet joint arthrosis, and aortic vascular calcification artificially inflate areal BMD T-scores at the lumbar spine. If the lumbar spine T-score appears incongruously “normal” in an elderly kyphotic patient with a hip T-score of -3.2, rely on the hip, femoral neck, or forearm 33% radius score for diagnosis.

12. Controversy

• Vertebral Augmentation: Efficacy vs. Sham Controls: In 2009, two randomized, double-blind, sham-controlled trials (Buchbinder et al. and Kallmes et al.) demonstrated no significant benefit of vertebroplasty over sham subcutaneous local anesthetic injection at 1 month. However, subsequent prospective randomized trials (INVEST, FREE, VAPOUR) targeting acute, highly painful fractures (< 6 weeks) with verified MRI bone marrow edema demonstrated significant pain reduction, improved physical function, and reduced opioid requirements. Clinical consensus now strongly favors augmentation in acute fractures refractory to conservative analgesia, while avoiding it in chronic, indolent collapses.
• Bisphosphonate “Drug Holidays” – Timing and Criteria: Prolonged bisphosphonate therapy (> 5 years oral, > 3 years IV) is associated with rare atypical femur fractures and osteonecrosis of the jaw, prompting the concept of a temporary drug holiday. Controversy persists regarding which patients can safely pause therapy. Current consensus suggests a drug holiday for moderate-risk patients who have achieved a stable hip T-score > -2.5 and have no recent fractures, while very high-risk patients (preexisting spine/hip fracture or T-score ≤ -2.5) should continue therapy or transition to an alternative class with ongoing reassessment every 2–3 years.
• Romosozumab Cardiovascular Safety Profile: The ARCH trial comparing romosozumab to alendronate identified a modest imbalance in adjudicated serious cardiovascular events (ischemic cardiac events and cerebrovascular accidents; 2.5% vs. 1.9%), though this imbalance was not observed in the placebo-controlled FRAME trial. Regulators implemented a black box warning advising against its use in patients with a myocardial infarction or stroke within the past year. Debate continues regarding whether this signal represents true biological drug toxicity vs. cardioprotective effects of the alendronate comparator arm.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996. doi:10.1016/s0140-6736(96)07088-2 [Level I: Randomized Controlled Trial]
• Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007. doi:10.1056/NEJMoa067312 [Level I: Randomized Controlled Trial]
• Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009. doi:10.1056/NEJMoa0809493 [Level I: Randomized Controlled Trial]
• Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001. doi:10.1056/NEJM200105103441904 [Level I: Randomized Controlled Trial]
• Cosman F, Crittenden DB, Adachi JD et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016. doi:10.1056/NEJMoa1607948 [Level I: Randomized Controlled Trial]

15. Master Class Pro-Tip

“When operating on severe osteoporotic bone, hardware failure is almost never a failure of metal, but a failure of host bone anchorage. In peritrochanteric hip fractures, obtain rigid load-sharing with an intramedullary nail and achieve a Tip-Apex Distance (TAD) strictly under 20 millimeters placed dead-center or inferior in the femoral head on the AP view to minimize cutout. In osteoporotic total hip arthroplasty or hemiarthroplasty, resist the temptation to use press-fit uncemented femoral stems; modern cement mantle technique distributes hoop stresses uniformly, virtually eliminates catastrophic intraoperative and early postoperative periprosthetic fractures, and allows the patient to bear immediate full weight on postoperative day zero.”

Master Class Surgical Pearl: Geriatric Fracture Fixation and Arthroplasty Anchorage